Summary
We present two methods for calculating Ki values of angiotensin converting enzyme (ACE) inhibitors, such as captopril, in anesthetized or conscious rabbits. Both methods are based on indicator-dilution type determinations of single pass transpulmonary metabolism of the ACE substrate benzoyl-phe-ala-pro (BPAP). The first method involves two determinations of Michaelis-Menten constants Km and Amax (product of Vmax and lung capillary plasma volume) of endothelial-bound ACE for BPAP. Thirty seconds before the second determination of kinetic constants, the inhibitor is administered iv (e. g. captopril, 12 nmol/kg). Comparisons of the apparent Km and Amax values, obtained after the inhibitor to the control values obtained from the first determination, provide Ki values. With the second method, the ratio Amax/Km is obtained, under first-order reaction conditions, before and 30 sec after administration of inhibitor. These apparent and control ratios are used to calculate Ki values. In both methods, plasma levels of the inhibitor at the time of the determination of apparent kinetic constants are estimated by injecting radio-labelled inhibitor (e. g. 3H-captopril), analyzing radioactivity in arterial samples and correcting for plasma protein binding. These methods are potentially applicable to the clinical evaluation of new ACE inhibitors, in vivo, under normal or pathologic conditions.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
J. D. Catravas and R. E. White, Kinetics of angiotensin converting enzyme and 5’-nucleotidase, in vivo, J. Appl. Physiol. 57: 1173–1181 (1984).
J. D. Catravas, Michaelis-Menten kinetics of pulmonary angiotensin converting enzyme in the conscious rabbit, in: “Kinin IV” (1986).
I. H. Segel, “Enzyme Kinetics,” Wiley, New York (1975).
J. W. Ryan, Assay of peptidase and protease enzymes, in vivo, Biochem. Pharmacol. 32: 2127–2137 (1983).
D. W. Cushman, H. S. Cheng, E. F. Sabo, and M. A. Ondetti, Design of new antihypertensive drugs: Potent and specific inhibitors of angiotensin converting enzyme, Prog. Cardiovasc. Pis. 21: 176–182 (1978).
D. W. Cushman, H. W. Cheng, E. F. Sabo, and M. A. Ondetti, Design of potent competitive inhibitors of angiotensin converting enzyme. Carboxyalkanoyl and marcapto alkanoyl amino acids, Biochem. 16: 5484–5491 (1977).
F. A. O. Mendelsohn, J. Csicsmann, and J. S. Hutchinson, Complex competitive and non-competitive inhibition of rat lung angio- tensin-converting enzyme by inhibitors containing thiol groups: Captopril and SA 446, Clin. Sci. 61: 277s–280s (1981).
X. Chen, B. R. Pitt, R. Moalli, and C. N. Gillis, Correlation between lung and plasma angiotensin converting enzyme and the hypotensive effect of captopril in conscious rabbits, J. Pharmacol. Exp. Ther. 229: 649–653 (1984).
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1986 Plenum Press, New York
About this chapter
Cite this chapter
Catravas, J.D., Anthony, B.L. (1986). In Vivo Determinations of Ki Values for Angiotensin Converting Enzyme Inhibitors. In: Greenbaum, L.M., Margolius, H.S. (eds) Kinins IV. Advances in Experimental Medicine and Biology, vol 198A. Springer, Boston, MA. https://doi.org/10.1007/978-1-4684-5143-6_61
Download citation
DOI: https://doi.org/10.1007/978-1-4684-5143-6_61
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4684-5145-0
Online ISBN: 978-1-4684-5143-6
eBook Packages: Springer Book Archive